April 22, 2026·6 min read·comparison, glp-1, metabolic
GLP-1 receptor agonists compared
Semaglutide vs Tirzepatide vs Retatrutide—mechanism, half-life, dosing, and the evidence gap.
Three GLP-1-based molecules now dominate the metabolic-research landscape: Semaglutide (NF-018), Tirzepatide (NF-019), and Retatrutide (NF-008/009). The historical narrative is straightforward—Semaglutide proved the class works, Tirzepatide doubled down on receptor coverage, and Retatrutide added a third axis. But the comparison that matters to a researcher isn't which one is "best." It's which one fits your endpoint and your tolerance for uncertainty.
Receptor coverage: from single to triple agonism
Semaglutide hits only the GLP-1 receptor. Tirzepatide binds both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) with roughly equal affinity. Retatrutide adds a third arm: it's a GLP-1/GIP/glucagon receptor agonist. This is not a trivial distinction—each additional receptor engagement shifts the biology measurably. GIP co-activation suppresses glucagon more aggressively than GLP-1 alone, further reducing hepatic glucose output. Glucagon receptor engagement in Retatrutide drives additional lipolysis through a distinct metabolic pathway, orthogonal to GLP-1's appetite suppression.
The result: magnitude of effect increases across the class. But so does the surface area for side effects and the uncertainty about long-term receptor-adaptation patterns.
Half-life and dosing practicality
Semaglutide's 7-day half-life anchors it to once-weekly dosing. Tirzepatide clears faster—approximately 5 days—but the dosing interval remains weekly. Retatrutide, in published phase 2 data, sits at roughly 5–6 days, also weekly. From a practical standpoint, the difference is negligible; all three sit firmly in the weekly-injection paradigm.
What matters more is the titration sensitivity. Skip the titration and nausea will be intolerable. Tirzepatide and Retatrutide trials have used similar graduated approaches, suggesting this is a class property, not a Semaglutide quirk.
Semaglutide's titration protocol is mandatory, not optional—starting at 0.25 mg and escalating every four weeks.
Body-composition effect: the size discrepancy
This is where the comparison gets honest. In the STEP 1 trial, Semaglutide at 2.4 mg weekly produced a placebo-adjusted weight loss of approximately 12.4% over 68 weeks in non-diabetic adults. That's the entry-level benchmark. In SURMOUNT-1, Tirzepatide at 15 mg weekly achieved approximately 20.9% placebo-adjusted weight loss over 72 weeks—substantially larger. In phase 2 data (TRIUMPH), Retatrutide showed approximately 24% at the 12 mg dose, the largest magnitude to date.
The obvious reading is that Tirzepatide and Retatrutide are simply superior. But context matters. Semaglutide's larger human dataset comes with longer post-marketing surveillance, allowing regulatory bodies to characterize safety and side-effect durability more precisely. The newer molecules have stronger acute effect sizes, but shallower long-term data. This is the classic trade-off in pharmacology: depth of evidence versus magnitude of response.
Molecule
Receptor(s)
t½ (days)
Maintenance dose range
Weight loss (phase 2/3)
Human RCT depth
Semaglutide
GLP-1 only
~7
1.0–2.4 mg weekly
~12.4%
Very deep (STEP/SUSTAIN/SELECT)
Tirzepatide
GLP-1 + GIP
~5
10–15 mg weekly
~20.9%
Moderate (SURMOUNT)
Retatrutide
GLP-1 + GIP + GCG
~5–6
8–12 mg weekly
~24%
Early phase 2
Evidentiary maturity
Semaglutide has been characterized in diabetic, non-diabetic, and cardiovascular-outcome populations. The STEP program alone enrolled thousands. SUSTAIN confirmed the dosing window and off-target effects in a diabetes cohort. SELECT demonstrated that cardiovascular benefit extends beyond weight loss. This is the gold standard for pharmaceutical characterization in 2026.
Tirzepatide has SURMOUNT (non-diabetic weight loss), SURPASS (diabetic), and emerging cardiovascular data, but the denominator is smaller and the long-term post-market window is shorter. Retatrutide is still in phase 2 and phase 3—the human dataset is measured in hundreds, not thousands.
What this means for a researcher: choosing Semaglutide means accepting the smallest acute effect size in exchange for the largest map of unknowns already known. Choosing Tirzepatide or Retatrutide means accepting larger effect size with a larger gap of ignorance around long-term side-effect drift, individual variability, and receptor-adaptation dynamics.
Side-effect profile and receptor selectivity
Semaglutide's most common off-target effect is GI (nausea, early satiety, vomiting) in the dose-titration window. This resolves with continued dosing. Tirzepatide adds a complication: the dual GIP engagement drives a notable incidence of nausea even after titration, and some users report sustained GI discomfort at maintenance doses. Retatrutide data is limited, but the addition of glucagon-receptor signaling raises the possibility of appetite-suppression effects so strong that they override hedonic eating even in the absence of nausea—a distinct mechanism, and not yet fully characterized in humans.
The broader point: older doesn't mean safer; it means more-thoroughly characterized. The safety profiles converge across the class, but Semaglutide's longer observational tail means the "rare" side effects have a better chance of being documented.
Research-protocol implications
If your endpoint is body composition and you value maximum certainty in long-term tolerability, Semaglutide remains the rational choice despite its smaller acute effect. If your endpoint is maximum magnitude of weight loss and you're comfortable with a shorter evidence window and closer monitoring for unexpected receptor-engagement effects, Tirzepatide is the move. Retatrutide is reserved for research contexts where the triple-agonist mechanism is specifically the question—not yet a general-population compound.
Stacking decisions follow. Some researchers pair a GLP-1 (Semaglutide) with a different mechanism entirely to target a secondary endpoint. Tirzepatide and Retatrutide are less commonly stacked, partly because their broader receptor coverage makes additive effects harder to predict and partly because the human data simply isn't deep enough yet to know whether synergy or interference dominates.
In the NeuroForge catalog
Semaglutide (NF-018) is the entry point. Tirzepatide (NF-019) is the high-magnitude alternative for researchers prioritizing acute effect size. Retatrutide (NF-008/009) is available for specialized triple-agonist research questions.
